SeaBeLife is a biotechnology company that develops small molecules designed to block regulated cell death pathways to treat acute, rare, and chronic diseases.
SeaBeLife has raised €6.1M across 4 funding rounds from 5 investors, most recently a Seed round in Oct 2025. Based in Roscoff, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-10-01 | Seed | €2.0M | iXLife,Femmes Business Angels,INext | View deal → |
| 2024-04-22 | Grant | €1.5M | i-Nov 2024 innovation competition | View deal → |
| 2023-09-27 | Other | €1.2M | iXLife | View deal → |
| 2022-03-14 | Other | €1.4M | Bpifrance | View deal → |
